FDA approves GSK’s Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
FDA approves GSK’s Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
Copyright © Louis Velazquez. All Rights Reserved.